Page 57 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Precision medicine and beyond in oncology

2. Peters GJ. From “targeted therapy” to targeted therapy. An open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307-
Anticancer Res. 2019;39(7):3341-3345. 1316.
doi: 10.21873/anticanres.13476 doi: 10.1016/S1470-2045(17)30679-4
3. Davis ID. An overview of cancer immunotherapy. Immunol 13. Salama AKS, Kim KB. Trametinib (GSK1120212) in
Cell Biol. 2000;78(3):179-195. the treatment of melanoma. Expert Opin Pharmacother.
doi: 10.1046/j.1440-1711.2000.00906.x 2013;14(5):619-627.
4. Mao X, Wu S, Huang D, Li C. Complications and doi: 10.1517/14656566.2013.770475
comorbidities associated with antineoplastic chemotherapy: 14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in
Rethinking drug design and delivery for anticancer therapy. advanced hepatocellular carcinoma. N Eng J Med.
Acta Pharm Sin B. 2024;14(7):2901-2926. 2008;359(4):378-390.
doi: 10.1016/j.apsb.2024.03.006 doi: 10.1056/NEJMoa0708857
5. Sterner RC, Sterner RM. CAR-T cell therapy: Current 15. Feng J, Lu PZ, Zhu GZ, et al. ACSL4 is a predictive biomarker
limitations and potential strategies. Blood Cancer J. of sorafenib sensitivity in hepatocellular carcinoma. Acta
2021;11(4):69. Pharmacol Sin. 2021;42(1):160-170.
doi: 10.1038/s41408-021-00459-7 doi: 10.1038/s41401-020-0439-x
6. Martín M, Pandiella A, Vargas-Castrillón E, et al. 16. Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-
Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol targeted therapies in cancer: A systematic review. Biomarker
Hematol. 2024;198:104355. Res. 2024;12(1):16.
doi: 10.1016/j.critrevonc.2024.104355 doi: 10.1186/s40364-024-00565-1
7. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year 17. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan
outcomes with pembrolizumab versus chemotherapy for in previously treated HER2-Low advanced breast cancer.
metastatic non-small-cell lung cancer with PD-L1 Tumor N Engl J Med. 2022;387(1):9-20.
proportion score 50%. J Clin Oncol. 2021;39(21):2339-2349.
doi: 10.1056/NEJMoa2203690
doi: 10.1200/jco.21.00174
18. Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan
8. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in (T-DXd) vs physician’s choice of chemotherapy (TPC)
untreated EGFR-mutated advanced non-small-cell lung
cancer. N Engl J Med. 2018;378(2):113-125. in patients (pts) with hormone receptor-positive (HR+),
human epidermal growth factor receptor 2 (HER2)-low or
doi: 10.1056/NEJMoa1713137 HER2-ultralow metastatic breast cancer (mBC) with prior
9. Turner NC, Ro J, André F, et al. Palbociclib in hormone- endocrine therapy (ET): Primary results from DESTINY-
receptor-positive advanced breast cancer. N Engl J Med. Breast06 (DB-06). J Clin Oncol. 2024;42(17 suppl):LBA1000.
2015;373(3):209-219. doi: 10.1200/JCO.2024.42.17_suppl.LBA1000
doi: 10.1056/NEJMoa1505270 19. Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan
10. Ingle JN, Tu D, Pater JL, et al. Intent-to-treat analysis of the in patients with HER2-mutant metastatic non-small-
placebo-controlled trial of letrozole for extended adjuvant cell lung cancer: Primary results from the randomized,
therapy in early breast cancer: NCIC CTG MA.17. Ann phase II DESTINY-Lung02 trial. J Clin Oncol.
Oncol. 2008;19(5):877-882. 2023;41(31):4852-4863.
doi: 10.1093/annonc/mdm566 doi: 10.1200/jco.23.01361
11. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant 20. Cortés J, Kim SB, Chung WP, et al. LBA1 Trastuzumab
plus palbociclib versus fulvestrant plus placebo for treatment deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in
of hormone-receptor-positive, HER2-negative metastatic patients (Pts) with HER2+ metastatic breast cancer (mBC):
breast cancer that progressed on previous endocrine therapy Results of the randomized phase III DESTINY-Breast03
(PALOMA-3): Final analysis of the multicentre, double- study. Ann Oncol. 2021;32:S1287-S1288.
blind, phase 3 randomised controlled trial. Lancet Oncol. doi: 10.1016/j.annonc.2021.08.2087
2016;17(4):425-439.
21. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T.
doi: 10.1016/s1470-2045(15)00613-0
Bystander killing effect of DS-8201a, a novel anti-human
12. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib epidermal growth factor receptor 2 antibody-drug conjugate,
plus trametinib in patients with previously untreated in tumors with human epidermal growth factor receptor 2
BRAFV600E-mutant metastatic non-small-cell lung cancer: heterogeneity. Cancer Sci. 2016;107(7):1039-1046.

Volume 8 Issue 3 (2025) 51 doi: 10.36922/ITPS025140018